awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36407379-4F0FB682-4D69-40C3-8D73-8DEF5501221E
Q36407379-4F0FB682-4D69-40C3-8D73-8DEF5501221E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36407379-4F0FB682-4D69-40C3-8D73-8DEF5501221E
Sorafenib.
P2860
Q36407379-4F0FB682-4D69-40C3-8D73-8DEF5501221E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36407379-4F0FB682-4D69-40C3-8D73-8DEF5501221E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2990ba028b5c8d3fbf069d39010b5fa1acad3fd5
P2860
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.